This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients.
Contact phone
(517) 364-2835
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Melanoma
Webform